Literature DB >> 17493863

How TNF was recognized as a key mechanism of disease.

Ian A Clark1.   

Abstract

This review summarizes the origins of the insight that excess production of pro-inflammatory cytokines caused a constellation of changes that contribute to pathophysiology of disease. This connection was made following the original 1975 TNF (tumor necrosis factor) publication from New York describing how activated macrophages kill tumors. The study caught the eye of a group in London who were trying to understand how the same in vivo macrophage activation would protect mice against the erythrocytic protozoan parasites that cause malaria and babesiosis. Based on collaborative research between these two groups, it was argued in 1981 that TNF and related cytokines initiated events that caused pathology, as well as parasite death within red cells in these infectious diseases. This proved to be a key conceptual advance. It was also argued that the pathology of bacterial sepsis logically had TNF origins. Once TNF was cloned in 1985, allowing its specific analysis in serum and neutralization in vivo, the involvement of this cytokine in infectious disease pathology was pursued by a number of groups. Some researchers found that once "their" cytokine was cloned and sequenced, they had been unwittingly expanding knowledge on TNF for several years. By the late 1980s excess TNF production was proposed to be central to acute systemic viral diseases. This family of cytokines is now at the centre of investigations to understand the mechanisms of acute systemic viral diseases, including influenza and the hemorrhagic viral diseases. With its implication as the master regulator of other inflammatory cytokines in the synovial membrane, TNF has also become the major cytokine in the pathogenesis of chronic inflammatory disease. Its neutralization has proven to be a potent treatment for rheumatoid arthritis and Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493863     DOI: 10.1016/j.cytogfr.2007.04.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  83 in total

Review 1.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

2.  Defining TNF-α- and LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease.

Authors:  Biljana Smiljanovic; Joachim R Grün; Marta Steinbrich-Zöllner; Bruno Stuhlmüller; Thomas Häupl; Gerd R Burmester; Andreas Radbruch; Andreas Grützkau; Ria Baumgrass
Journal:  J Mol Med (Berl)       Date:  2010-07-17       Impact factor: 4.599

3.  Systemic inflammatory responses in progressing periodontitis during pregnancy in a baboon model.

Authors:  J L Ebersole; M J Steffen; S C Holt; L Kesavalu; L Chu; D Cappelli
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

Review 4.  Tumor necrosis factor-α signaling in macrophages.

Authors:  Narayanan Parameswaran; Sonika Patial
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

5.  Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α and growth arrest-specific gene 6.

Authors:  Xueying Feng; Tingting Deng; Yue Zhang; Shaobo Su; Chiju Wei; Daishu Han
Journal:  Immunology       Date:  2010-10-29       Impact factor: 7.397

Review 6.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

7.  TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Authors:  Martin Bitzan; Sima Babayeva; Anil Vasudevan; Paul Goodyer; Elena Torban
Journal:  Pediatr Nephrol       Date:  2012-04-27       Impact factor: 3.714

Review 8.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

9.  Mao-to Prolongs the Survival of and Reduces TNF-alpha Expression in Mice with Viral Myocarditis.

Authors:  Zhu Shijie; Junji Moriya; Jun'ichi Yamakawa; Rui Chen; Takashi Takahashi; Hiroyuki Sumino; Takeshi Nakahashi; Kunimitsu Iwai; Shigeto Morimoto; Nobuo Yamaguchi; Tsugiyasu Kanda
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-24       Impact factor: 2.629

Review 10.  Endotoxin and cancer.

Authors:  Jessica I Lundin; Harvey Checkoway
Journal:  Environ Health Perspect       Date:  2009-05-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.